Alexium International Group Ltd (ASX: AJX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alexium International Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$17.34 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.58 billion
Earnings per share
-0.004
Dividend per share
N/A
Year To Date Return
-21.43%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alexium International Group Ltd (ASX: AJX)
Latest News
⏸️ ASX Shares
What's going on with the Alexium (ASX:AJX) share price?
Share Gainers
Alexium (ASX:AJX) share price rockets 34% on sales update
Share Market News
Here's why the Alexium (ASX:AJX) share price surged 9% today
Share Gainers
Why the Alexium share price is up 25% this week
Share Gainers
These small cap ASX shares have started the week on a high
⏸️ Investing
Why these 4 ASX shares started the week in the red
⏸️ Investing
Why shares of Alexium International Group Ltd are down today
⏸️ Investing
One investment idea for FY18 that you've probably missed
⏸️ Investing
The Alexium International Group Ltd share price is up 21% this week
⏸️ Investing
Why these 4 ASX shares have posted solid gains today
⏸️ Investing
Alexium International Group Ltd: A promising small-cap?
⏸️ Investing
Why these 5 ASX shares have rocketed higher today
1❯
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 26 Mar 2004 | $0.0200 | 100.00% | Interim | 15 Apr 2004 |
AJX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alexium International Group Ltd
Alexium International Group Ltd is engaged in the development of specialty chemicals. Its only operating segment is the development and commercialization of its proprietary flame retardant (FR) and phase change material (PCM) chemistries, cooling products for bedding, and selling its specialized chemistry to customers. Geographically, it derives a majority of its revenue from the United States and also has a presence in Australia. The company's product solutions include Alexicool, Alexiflam NF, Eclipsys, Alexiflam, and Alexiguard.
AJX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.01 | $0.00 | 0.00% | 49,257 | $0.01 | $0.01 | $0.01 |
| 19 Dec 2024 | $0.01 | $0.00 | 0.00% | 71,000 | $0.01 | $0.01 | $0.01 |
| 18 Dec 2024 | $0.01 | $0.00 | 0.00% | 87,789 | $0.01 | $0.01 | $0.01 |
| 17 Dec 2024 | $0.01 | $0.00 | 0.00% | 100,000 | $0.01 | $0.01 | $0.01 |
| 16 Dec 2024 | $0.01 | $0.00 | 0.00% | 695,006 | $0.02 | $0.02 | $0.01 |
| 13 Dec 2024 | $0.02 | $0.00 | 0.00% | 267,440 | $0.01 | $0.02 | $0.01 |
| 12 Dec 2024 | $0.01 | $0.00 | 0.00% | 18,000 | $0.01 | $0.01 | $0.01 |
| 11 Dec 2024 | $0.01 | $0.00 | 0.00% | 56,816 | $0.01 | $0.01 | $0.01 |
| 10 Dec 2024 | $0.01 | $0.00 | 0.00% | 1,017,802 | $0.01 | $0.01 | $0.01 |
| 06 Dec 2024 | $0.01 | $0.00 | 0.00% | 326,045 | $0.01 | $0.01 | $0.01 |
| 04 Dec 2024 | $0.01 | $0.00 | 0.00% | 2,290,313 | $0.01 | $0.01 | $0.01 |
| 03 Dec 2024 | $0.01 | $0.00 | 0.00% | 150,000 | $0.01 | $0.01 | $0.01 |
| 02 Dec 2024 | $0.01 | $0.00 | 0.00% | 399,657 | $0.01 | $0.01 | $0.01 |
| 29 Nov 2024 | $0.01 | $0.00 | 0.00% | 25,348 | $0.01 | $0.01 | $0.01 |
| 27 Nov 2024 | $0.01 | $0.00 | 0.00% | 150,766 | $0.01 | $0.01 | $0.01 |
| 26 Nov 2024 | $0.01 | $0.00 | 0.00% | 2,945 | $0.01 | $0.01 | $0.01 |
| 25 Nov 2024 | $0.01 | $0.00 | 0.00% | 450,000 | $0.01 | $0.01 | $0.01 |
| 22 Nov 2024 | $0.01 | $0.00 | 0.00% | 12,000 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Dec 2024 | Simon Moore | Issued | 2,632,681 | $31,592 |
Director remuneration.
|
| 20 Sep 2024 | Carl Dennis | Issued | 4,084,530 | $44,929 |
Director remuneration.
|
| 20 Sep 2024 | Paul Stenson | Issued | 4,084,530 | $44,929 |
Director remuneration.
|
| 20 Sep 2024 | Simon Moore | Issued | 3,651,206 | $40,163 |
Director remuneration.
|
| 21 May 2024 | Simon Moore | Issued | 4,184,624 | $46,030 |
Director remuneration.
|
| 08 May 2024 | Simon Moore | Buy | 549,306,692 | $8,239,600 |
Conversion of convertible notes.
|
| 07 May 2024 | Simon Moore | Issued | 19,939,214 | $259,209 |
Placement.
|
| 07 May 2024 | Carl Dennis | Issued | 14,954,410 | $94,407 |
Placement. As per announcement on 09-05-2024
|
| 06 May 2024 | Carl Dennis | Issued | 100,430,205 | $1,305,592 |
Rights issue.
|
| 06 May 2024 | Simon Moore | Issued | 133,906,940 | $1,740,790 |
Rights issue.
|
| 06 May 2024 | Carl Dennis | Issued | 171,144 | $2,224 |
Rights issue.
|
| 03 May 2024 | Robert (Bob) Brookins | Issued | 3,850,000 | $50,050 |
Placement. As per announcement on 03-05-2024
|
| 03 May 2024 | Paul Stenson | Issued | 11,500,000 | $149,500 |
Placement.
|
| 03 May 2024 | William (Billy) Blackburn | Issued | 12,000,000 | $156,000 |
Placement.
|
| 12 Jan 2024 | Robert (Bob) Brookins | Issued | 6,505,703 | $91,079 |
Issue of securities. 19,882,851 Share Appreciation Rights
|
| 12 Jan 2024 | William (Billy) Blackburn | Issued | 6,712,233 | $93,971 |
Issue of securities. 29,555,881 Share Appreciation Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Simon Colinton Moore | Non-Executive DirectorInterim Chairman | Feb 2020 |
Mr Moore is the Senior Partner of the investment firm, Colinton Capital Partners. Prior to establishing Colinton Capital Partners in 2017, Mr Moore was a Global Partner of The Carlyle Group having established their operation in Australia in 2005. In his time at The Carlyle Group, he oversaw the Firm's investments in and served on the Boards of Directors of Coates Hire, Healthscope and QUBE. He is a member of the Risk Committee.
|
| Dr Robert (Bob) Brookins | Executive Director | May 2018 |
Dr Brookins has more than 15 years of experience in organic synthesis and materials chemistry. Dr Brookins led the development and commercialisation of Alexium's phase change material (PCM) platform technologies and the AlexiCool product line, which is the foundation of the Company's success in the bedding and top-of-bed markets. He is a member of the Risk Committee.
|
| Dr Paul Henry Stenson | Non-Executive Director | Jun 2020 |
Dr Stenson has career with the research, development, manufacture, and commercialisation of new materials in the fields of coatings, adhesives, nonwovens, and pharmaceuticals. He is the Chair of the Risk Committee.
|
| Mr William (Billy) Timothy Blackburn | Chief Executive OfficerManaging Director | Sep 2022 |
Mr Blackburn has over 25 years of experience in general management, with a track record of driving commercial growth.
|
| Mr T Randall Lane | Non-Executive Director | Jul 2024 |
--
|
| Mr Martyn Strickland | Non-Executive Director | Jul 2024 |
--
|
| Mr James Williamson | Interim Non-Executive Director | Nov 2024 |
Mr Williamson has over 28 years of experience in financial markets and is the Co-Founder and Chief Investment Officer of Wentworth Williamson Management, a substantial shareholder of Alexium International Group Limited. Founded in 2013, Wentworth Williamson Management is a private Australian-based value fund manager with both equity and private credit funds. Prior to Wentworth Williamson, Mr Williamson worked for Allan Gray Australia and prior to that he was Portfolio Manager of the Investec Australian Equity Fund.
|
| Mr Mark Andrew Licciardo | Company Secretary | Mar 2020 |
-
|
| Mark Andrew Licciardo | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Colinton Capital Partners Pty Ltd <Colinton Cp Fund 1 (A) A/C> | 628,458,023 | 40.23% |
| Sandhurst Trustees Ltd <Wentworth Williamson A/C> | 170,573,358 | 10.92% |
| Colinton Capital Partners Pty Ltd | 163,617,640 | 10.47% |
| Dr Stuart Lloyd Phillips & Mrs Fiona Jane Phillips <SL & FJ Phillips Pens F A/C> | 53,507,499 | 3.43% |
| Dr Stuart Lloyd Phillips & Mrs Fiona Jane Phillips <SL & FJ Phillips S/F A/C> i | 31,399,324 | 2.01% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 22,991,567 | 1.47% |
| N & G Td Proprietary Limited <N & G Td Super Fund A/C> | 20,000,000 | 1.28% |
| Lucky Pom Pty Limited <Grayson A/C> | 16,000,000 | 1.02% |
| Dr Elyse Jane Phillips | 13,332,692 | 0.85% |
| William T Blackburn Jr | 12,000,000 | 0.77% |
| Dr Paul Stenson | 11,500,000 | 0.74% |
| Rosheen Garnon | 11,483,822 | 0.74% |
| HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 10,000,000 | 0.64% |
| Ducky'S Lifeline Pty Ltd <The R Edwards Super A/C> | 8,320,552 | 0.53% |
| BNP Paribas Noms Pty Ltd | 8,268,661 | 0.53% |
| Mr Ian Morton & Mrs Deborah Morton <Debian Super Fund A/C> | 7,305,359 | 0.47% |
| Citicorp Nominees Pty Limited | 6,932,159 | 0.44% |
| Mr Robert Neal Brookins | 6,762,662 | 0.43% |
| Mabeth Pty Ltd | 6,000,000 | 0.38% |
| Mr Martin Keith Thomas & Mrs Helen Patricia Thomas | 5,431,500 | 0.35% |
